| ID Source | ID |
|---|---|
| PubMed CID | 3085877 |
| CHEMBL ID | 357047 |
| SCHEMBL ID | 7844916 |
| MeSH ID | M0256697 |
| Synonym |
|---|
| 6,7-dihydropyrrolo[2,3-c]azepine-4,8(1h,5h)-dione |
| aldisine |
| 72908-87-3 |
| 6,7-dihydro-1h,5h-pyrrolo[2,3-c]azepine-4,8-dione |
| CHEMBL357047 , |
| aldisin |
| bdbm50108777 |
| FT-0693021 |
| AKOS006286699 |
| 1,5,6,7-tetrahydropyrrolo[2,3-c]azepine-4,8-dione |
| unii-tdf8482e6r |
| tdf8482e6r , |
| pyrrolo(2,3-c)azepine-4,8(1h,5h)-dione, 6,7-dihydro- |
| AAPGLCCSVSGLFH-UHFFFAOYSA-N |
| 6,7-dihydropyrrolo[2,3-c]azepin-4,8(1h, 5h)dione |
| DTXSID40223211 |
| mfcd08166501 |
| SCHEMBL7844916 |
| pyrrolo[2,3-c]azepine-4,8(1h,5h)-dione, 6,7-dihydro- |
| SR-00000001856-1 |
| sr-00000001856 |
| DS-4871 |
| 1h,4h,5h,6h,7h,8h-pyrrolo[2,3-c]azepine-4,8-dione |
| C76318 |
| 6,7-dihydropyrrolo(2,3-c)azepine-4,8(1h,5h)-dione |
| 1,5,6,7-tetrahydropyrrolo(2,3-c)azepine-4,8-dione |
| B0001-042431 |
| A866176 |
| XCA90887 |
| 6,7-dihydropyrrolo[2,3-c]azepine-4,8(1h,5h);-dione |
| CS-0187182 |
| EN300-1228837 |
| Z1198176330 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | IC50 (µMol) | 2.5000 | 0.0010 | 0.3349 | 8.9000 | AID164360 |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 2.5000 | 0.0004 | 0.7649 | 12.5000 | AID126782 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 (µMol) | 2.5000 | 0.0003 | 1.6878 | 9.2000 | AID126782 |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | IC50 (µMol) | 2.5000 | 0.0002 | 0.6813 | 9.7000 | AID126618; AID164360 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID685396 | Inhibition of recombinant CDK2/cyclin A expressed in Sf21 cells using histone H1 as substrate at 10 uM after 10 mins by scintillation counting in presence of [32P]ATP | 2012 | European journal of medicinal chemistry, Oct, Volume: 56 | Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine. |
| AID126618 | Inhibition of MEK1 phosphorylation by activated human recombinant Raf | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2 | Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). |
| AID604318 | Inhibition of human recombinant PTP1B assessed as inhibition of para-nitrophenyl phosphate to para-nitrophenol conversion at 100 uM by spectrophotometry | 2011 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14 | Pyrrolo[2,3-c]azepine derivatives: a new class of potent protein tyrosine phosphatase 1B inhibitors. |
| AID126782 | Inhibition of Mitogen-activated protein kinase (MAPK)phosphorylation by activated MEK-1 | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2 | Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). |
| AID685393 | Antiproliferative activity against human LoVo cells after 96 hrs by MTT assay | 2012 | European journal of medicinal chemistry, Oct, Volume: 56 | Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine. |
| AID685392 | Antiproliferative activity against human A549 cells after 96 hrs by MTT assay | 2012 | European journal of medicinal chemistry, Oct, Volume: 56 | Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine. |
| AID45091 | Inhibition of human adenocarcinoma cell line Caco-2 proliferation | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2 | Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). |
| AID102170 | Inhibition of human adenocarcinoma cell line LoVo proliferation | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2 | Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). |
| AID400415 | Toxicity in brine shrimp | 1998 | Journal of natural products, Mar, Volume: 61, Issue:3 | A new lysine derivative and new 3-bromopyrrole carboxylic acid derivative from two marine sponges. |
| AID685395 | Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay | 2012 | European journal of medicinal chemistry, Oct, Volume: 56 | Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine. |
| AID164360 | Inhibition of kinase activity of Raf/MEK/ERK kinase cascade in ELISA | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2 | Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). |
| AID685394 | Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay | 2012 | European journal of medicinal chemistry, Oct, Volume: 56 | Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.85) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||